<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129762</url>
  </required_header>
  <id_info>
    <org_study_id>DI/19/301/03/020</org_study_id>
    <nct_id>NCT04129762</nct_id>
  </id_info>
  <brief_title>Effect of a Diet Without Non-caloric Sweeteners on Gastrointestinal Symptoms in Patients With IBS and Dyspepsia</brief_title>
  <acronym>IBS</acronym>
  <official_title>Effect of a Diet Without Non-caloric Sweeteners on Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome and Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Digestive Functional Disorders (DFD), represent 50% of medical check ups, the symptoms&#xD;
      interfere with patients quality of life and generate high health costs. On the other hand,&#xD;
      with the worldwide overweight and obesity increase,causing an over production of low-calorie&#xD;
      products, which increase the non-caloric sweeteners (NCS) consumption.&#xD;
&#xD;
      Hypothesis: A diet without NCS will reduce gastrointestinal symptoms in volunteers with&#xD;
      dyspepsia and IBS.&#xD;
&#xD;
      Objective: To asses the effect of a diet without NCS, on the gastrointestinal symptoms in&#xD;
      patients with dyspepsia and IBS.&#xD;
&#xD;
      Secondary Objectives: To compare the effect of a diet without NCS against a diet with NCS on&#xD;
      anthropometry, changes in body composition, biochemical parameters, glucose and insulin. To&#xD;
      asses the change in the gut microbiota using real-time PCR (polymerase chain reaction)&#xD;
&#xD;
      Methodology: it will be an experimental, open, parallel, controlled study lasting 12 weeks,&#xD;
      patients with dyspepsia or IBS will be randomized assigned to a diet with or without NCS.&#xD;
&#xD;
      Laboratory studies, dietary and symptoms questionnaires, anthropometry measurements and&#xD;
      faecal sample will be carried out.&#xD;
&#xD;
      Analysis Results: A double data capture will be carried out to minimize errors, for the&#xD;
      statistical analysis of using the Statistical Package for the Social Sciences (SPSS) version&#xD;
      25, descriptive statistics will be used to report the baseline data of the volunteers. Using&#xD;
      means and standard deviation, the variables of gastrointestinal symptoms will be used a&#xD;
      chi-square test and a p &lt;0.05 will be considered significant. Different analyzes will be done&#xD;
      to evaluate volunteers with IBS and those with dyspepsia. For the intestinal microbiota&#xD;
      analysis, a comparison will be made between the percentages of Firmicutes, Bacteroidetes and&#xD;
      Actinobacteria of sample 1 and 2 and a chi-square test will be performed considering a p&#xD;
      &lt;0.05 significant&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment will be carried out in the gastroenterology service, where patients will have&#xD;
      their diagnosis of IBS or dyspepsia, participants are invited to participate in the study to&#xD;
      subsequently sign the informed consent.&#xD;
&#xD;
      Once signed the patient is scheduled for blood studies, their nutritional evaluation will be&#xD;
      carried out and their menu will be delivered.&#xD;
&#xD;
      Patients will be followed for 12 weeks to re-conduct their nutritional evaluation and&#xD;
      laboratory studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The diet without NCS will change the frequency of gastrointestinal symptoms in patients with IBS.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Using ROME III criteria, the frequency of patients who present with gastrointestinal symptoms is monitored.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The diet without NCS will change the frequency of gastrointestinal symptoms in patients with dyspepsia.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Using ROME III criteria, the frequency of patients who present with gastrointestinal symptoms is monitored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes in the weight of the patients with irritable bowel syndrome, from the beginning of the diet, at 6 weeks and at 12 weeks</measure>
    <time_frame>at the week 1, 6 and 12</time_frame>
    <description>For the evaluation we are going to use weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the weight of the patients with dyspepsia, from the beginning of the diet, at 6 weeks and at 12 weeks</measure>
    <time_frame>at the week 1, 6 and 12</time_frame>
    <description>For the evaluation we are going to use weight in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the body composition in patients with irritable bowel syndrome, from the beginning of the diet, at 6 weeks and at 12 weeks</measure>
    <time_frame>at the week 1, 6 and 12</time_frame>
    <description>We are going to use RJL system IV for body composition we will report the changes in percentage of water, fat and muscle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the body composition in patients with dyspepsia, from the beginning of the diet, at 6 weeks and at 12 weeks</measure>
    <time_frame>at the week 1, 6 and 12</time_frame>
    <description>We are going to use RJL system IV for body composition we will report the changes in percentage of water, fat and muscle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the waist circumference in patients with irritable bowel syndrome, from the beginning of the diet, at 6 weeks and at 12 weeks</measure>
    <time_frame>at the week 1, 6 and 12</time_frame>
    <description>For the evaluation we are going to use waist circumference in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the waist circumference in patients with dyspepsia, from the beginning of the diet, at 6 weeks and at 12 weeks</measure>
    <time_frame>at the week 1, 6 and 12</time_frame>
    <description>For the evaluation we are going to use waist circumference in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in glucose in the patients with irritable bowel syndrome, from the beginning and end of the diet</measure>
    <time_frame>at the week 1 and 12</time_frame>
    <description>For the changes we are going to use glucose in mg / dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in glucose in the patients with dyspepsia, from the beginning and end of the diet</measure>
    <time_frame>at the week 1 and 12</time_frame>
    <description>For the changes we are going to use glucose in mg / dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes insulin in the patients with irritable bowel syndrome, at the beginning and end of the diet</measure>
    <time_frame>at the week 1 and 12</time_frame>
    <description>For the serological changes in the insulin we are going to use the measure in IU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes insulin in the patients with dyspepsia, at the beginning and end of the diet</measure>
    <time_frame>at the week 1 and 12</time_frame>
    <description>For the serological changes in the insulin we are going to use the measure in IU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the lipids profile in the patients with irritable bowel syndrome, at the beginning and end of the diet</measure>
    <time_frame>at the week 1 and 12</time_frame>
    <description>For the serological changes in the lipid profile we are going to use triglycerides in mg/dl, total cholesterol in mg/dl, HDL in mg/dl, cholesterol, LDL in mg / dl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the lipids profile in the patients with dyspepsia, at the beginning and end of the diet.</measure>
    <time_frame>at the week 1 and 12</time_frame>
    <description>For the serological changes in the lipid profile we are going to use triglycerides in mg/dl, total cholesterol in mg/dl, HDL in mg/dl, cholesterol, LDL in mg / dl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the diet without NCS in gut microbiota in patients with irritable bowel syndrome at the beginning and end of the diet</measure>
    <time_frame>at the week 1 and 12</time_frame>
    <description>Using real-time PCR, the effect of the diet without NCS, on the gut microbiota of patients with irritable bowel syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the diet without NCS in gut microbiota in patients with dyspepsia at the beginning and end of the diet</measure>
    <time_frame>at the week 1 and 12</time_frame>
    <description>Using real-time PCR, the effect of the diet without NCS, on the gut microbiota of patients with dyspepsia</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>IBS - Irritable Bowel Syndrome</condition>
  <condition>Functional Gastrointestinal Disorders</condition>
  <arm_group>
    <arm_group_label>Diet without NCS in irritable bowl syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it does not contain any products with NCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet with NCS in irritable bowl syndrome</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it contain any products with NCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet without NCS in dyspepsia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with dyspepsia are assigned to a 5 meals divided diet. In which it does not contain any products with NCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet with NCS in dyspepsia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with dyspepsia are assigned to a 5 meals divided diet. In which it contain any products with NCS</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet without NCS</intervention_name>
    <description>A standard diet in terms of macronutrients will be calculated.&#xD;
55% Carbohydrates&#xD;
20% protein&#xD;
25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.&#xD;
The menu will not contain products with NCS.</description>
    <arm_group_label>Diet without NCS in dyspepsia</arm_group_label>
    <arm_group_label>Diet without NCS in irritable bowl syndrome</arm_group_label>
    <other_name>Diet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet with NCS</intervention_name>
    <description>A standard diet in terms of macronutrients will be calculated.&#xD;
55% Carbohydrates&#xD;
20% protein&#xD;
25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.&#xD;
The menu will contain products with NCS.</description>
    <arm_group_label>Diet with NCS in dyspepsia</arm_group_label>
    <arm_group_label>Diet with NCS in irritable bowl syndrome</arm_group_label>
    <other_name>Diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both sexes from 18 to 65 years old&#xD;
&#xD;
          -  Diagnosis of IBS or Dyspepsia&#xD;
&#xD;
          -  Patients with dyspepsia must have endoscopy&#xD;
&#xD;
          -  Normal or overweight BMI (18.5 - 29.9 kg / m2)&#xD;
&#xD;
          -  Not suffering from chronic non-communicable or infectious diseases&#xD;
&#xD;
          -  Follow the meal plan that is being given.&#xD;
&#xD;
          -  Do not consume alcoholic beverages&#xD;
&#xD;
          -  No Smoking&#xD;
&#xD;
          -  Signing of the informed consent letter expressing your desire to participate as&#xD;
             volunteers in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  People who at the time of their selection are studying with acute illness of any kind&#xD;
&#xD;
          -  Type 1 or 2 diabetes.&#xD;
&#xD;
          -  Diagnosis of malabsorption syndrome&#xD;
&#xD;
          -  Neoplasia&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Medicine that affects the gastrointestinal tract&#xD;
&#xD;
          -  Women who at the time of their selection are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nallely Bueno Hernendez, PhD</last_name>
    <phone>27892000</phone>
    <phone_ext>5654</phone_ext>
    <email>nallely_bh5@yahoo.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Viridiana M Mendoza Martinez, B.S.</last_name>
    <phone>2789200</phone>
    <phone_ext>5654</phone_ext>
    <email>dinvestigacionhgm@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nallely Hernandez Bueno</name>
      <address>
        <city>Mexico City</city>
        <state>Cuauhtemoc</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nalllely Bueno Hernandez, PhD</last_name>
      <phone>27892000</phone>
      <phone_ext>5654</phone_ext>
      <email>nallely_bh5@yahoo.com.mx</email>
    </contact>
    <contact_backup>
      <last_name>Viridiana M Mendoza Martinez, B.S.</last_name>
      <phone>5529370762</phone>
      <email>dinvestigacionhgm@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>Nallely Bueno Hern√°ndez</investigator_full_name>
    <investigator_title>Investigator In Medical Science B</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

